Coherus Biosciences

Surface Oncology, Inc. is a clinical-stage immuno-oncology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies. The company specializes in creating human immunoglobulin isotype G4 monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, which targets CD73; SRF617, which inhibits CD39; SRF388, aimed at interleukin 27; and SRF813, which targets CD112R. Additionally, Surface Oncology is advancing several preclinical programs that address other critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established strategic collaborations with Novartis Institutes for Biomedical Research and Merck Sharp & Dohme Corp. to advance the development of its therapies, including evaluating the combination of SRF617 with Merck’s KEYTRUDA. Founded in 2014, Surface Oncology aims to leverage novel immunotherapy targets and insights into cancer immuno-biology to enhance anti-tumor immune responses.

InteKrin Therapeutics is a clinical-stage, privately held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for neuroendocrine, metabolic, and immune disorders. The company is focused on addressing critical healthcare challenges, particularly in diseases such as diabetes, metabolic syndrome, and cancer, which require new treatment options to improve patient outcomes and reduce healthcare costs. InteKrin is actively in-licensing both early- and late-stage compounds aimed at exploring the intricate hormonal relationships influencing metabolism, insulin resistance, and obesity. Among its key developments is INT131, a non-TZD peroxisome proliferator-activated receptor gamma modulator designed to treat Relapsing Remitting Multiple Sclerosis, which seeks to provide neuroprotection while halting the progression of this serious condition.